Shuanglu Pharmaceutical announced that in the first half of 2026, net profit losses attributable to shareholders of listed companies are expected to be 251 million yuan to 269 million yuan, a year-on-year decrease of 121 million yuan, a year-on-year decrease of 307.36%-322.23%; net profit after deducting non-recurring profit and loss will be 2.8 million yuan to 4 million yuan, down 84.62%-89.23% from 260.44 million yuan in the same period last year. Reasons for changes in performance: Among non-recurring profits and losses, fair value changes in trading financial assets and other illiquid financial assets were large, mainly due to fluctuations in the stock prices of Changfeng Pharmaceutical and Xuanzhu Biotech, which were listed on the Hong Kong Stock Exchange in October 2025. The profit and loss from fair value changes from January to June 2026 was about -310 million yuan, a decrease of about 420 million yuan compared with the same period last year; after deducting the decline in non-net profit, the main product prices led to a year-on-year decrease in operating income and a decline in gross margin.

Shuanglu Pharmaceutical announced that in the first half of 2026, net profit losses attributable to shareholders of listed companies are expected to be 251 million yuan to 269 million yuan, a year-on-year decrease of 121 million yuan, a year-on-year decrease of 307.36%-322.23%; net profit after deducting non-recurring profit and loss will be 2.8 million yuan to 4 million yuan, down 84.62%-89.23% from 260.44 million yuan in the same period last year. Reasons for changes in performance: Among non-recurring profits and losses, fair value changes in trading financial assets and other illiquid financial assets were large, mainly due to fluctuations in the stock prices of Changfeng Pharmaceutical and Xuanzhu Biotech, which were listed on the Hong Kong Stock Exchange in October 2025. The profit and loss from fair value changes from January to June 2026 was about -310 million yuan, a decrease of about 420 million yuan compared with the same period last year; after deducting the decline in non-net profit, the main product prices led to a year-on-year decrease in operating income and a decline in gross margin.